{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T09:45:33Z","timestamp":1763545533457,"version":"3.45.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"crossref","award":["FNOL, 00098892"],"award-info":[{"award-number":["FNOL, 00098892"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004240","name":"Akademie V\u011bd \u010cesk\u00e9 Republiky","doi-asserted-by":"crossref","award":["NU22-03-00182"],"award-info":[{"award-number":["NU22-03-00182"]}],"id":[{"id":"10.13039\/501100004240","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The simultaneous occurrence of Hodgkin lymphoma (HL) and ovarian carcinoma (OC) is rare and presents unique challenges in diagnosis and treatment. Circulating tumour DNA (ctDNA) offers a minimally invasive method for detecting minimal residual disease in both malignancies. We present the case of a 42-year-old woman with relapsed HL and advanced high-grade serous OC, treated with nivolumab, a PD-L1 inhibitor. After surgery and chemotherapy for OC, she received salvage therapy for cHL, including autologous stem cell transplantation. During the therapy, the patient was monitored using PET\/CT and ctDNA analysis. CtDNA analysis detected a Hodgkin-driven compound mutation in the STAT6 gene (N417Y\/N421S) allowing early relapse detection and treatment adjustments, detected progression of the disease led to nivolumab initiation. The mutation was used to monitor minimal residual disease (MRD). For ovarian carcinoma, presence of the BRAF V600E mutation as the marker was detected from archival paraffin-embedded ovarian tissue collected at the time of diagnosis, during ctDNA monitoring, BRAF V600E associated with OC remained undetectable, aligning with remission. This case highlights the potential of ctDNA to improve monitoring of concurrent malignancies, especially during immunotherapy, where PET\/CT may lead to false-positive results. It is the first reported case of nivolumab treatment for chemo-refractory relapsed HL and OC, demonstrating the utility of ctDNA in managing dual malignancies.<\/jats:p>","DOI":"10.1007\/s12672-025-03792-6","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:10:24Z","timestamp":1762521024000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The role of liquid biopsy in the management of concurrent Hodgkin lymphoma and ovarian carcinoma treated with nivolumab"],"prefix":"10.1007","volume":"16","author":[{"given":"Veronika","family":"Han\u00e1\u010dkov\u00e1","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Grohmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"Urb\u00e1nkov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hana","family":"\u0160tudentov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Buri\u00e1nkov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lenka","family":"Henzlov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom\u00e1\u0161","family":"Papaj\u00edk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronika","family":"Bachanov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00edt","family":"Proch\u00e1zka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"3792_CR1","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","volume":"385","author":"CH Moskowitz","year":"2015","unstructured":"Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, et al. Brentuximab Vedotin as consolidation therapy after autologous stem-cell transplantation in patients with hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Lond Engl. 2015;385:1853\u201362. https:\/\/doi.org\/10.1016\/S0140-6736(15)60165-9.","journal-title":"Lancet Lond Engl"},{"key":"3792_CR2","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1080\/10428194.2021.2010060","volume":"63","author":"V Camus","year":"2022","unstructured":"Camus V, Viennot M, L\u00e9v\u00eaque E, Viailly P-J, Tonnelet D, Veresezan E-L, et al. Circulating tumor DNA in primary mediastinal large B-cell lymphoma versus classical hodgkin lymphoma: a retrospective study. Leuk Lymphoma. 2022;63:834\u201344. https:\/\/doi.org\/10.1080\/10428194.2021.2010060.","journal-title":"Leuk Lymphoma"},{"key":"3792_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1097\/00004347-200001000-00003","volume":"19","author":"SG Silverberg","year":"2000","unstructured":"Silverberg SG. Histopathologic grading of ovarian carcinoma: A review and proposal. Int J Gynecol Pathol. 2000;19:7.","journal-title":"Int J Gynecol Pathol"},{"key":"3792_CR4","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/cncr.27782","volume":"119","author":"RN Grisham","year":"2013","unstructured":"Grisham RN, Iyer G, Garg K, DeLair D, Hyman DM, Zhou Q, et al. BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer. Cancer. 2013;119:548\u201354. https:\/\/doi.org\/10.1002\/cncr.27782.","journal-title":"Cancer"},{"key":"3792_CR5","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.ygyno.2016.08.320","volume":"143","author":"A Kaldawy","year":"2016","unstructured":"Kaldawy A, Segev Y, Lavie O, Auslender R, Sopik V, Narod SA. Low-grade serous ovarian cancer: A review. Gynecol Oncol. 2016;143:433\u20138. https:\/\/doi.org\/10.1016\/j.ygyno.2016.08.320.","journal-title":"Gynecol Oncol"},{"key":"3792_CR6","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.2165\/11591720-000000000-00000","volume":"71","author":"RW Naumann","year":"2011","unstructured":"Naumann RW, Coleman RL. Management strategies for recurrent Platinum-Resistant ovarian cancer. Drugs. 2011;71:1397\u2013412. https:\/\/doi.org\/10.2165\/11591720-000000000-00000.","journal-title":"Drugs"},{"key":"3792_CR7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.3397","author":"J Hamanishi","year":"2015","unstructured":"Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Murayama T, et al. Safety and antitumor activity of Anti\u2013PD-1 Antibody, Nivolumab, in patients with Platinum-Resistant ovarian cancer. J Clin Oncol. 2015. https:\/\/doi.org\/10.1200\/JCO.2015.62.3397.","journal-title":"J Clin Oncol"},{"key":"3792_CR8","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the world health organization classification of lymphoid neoplasms. Blood. 2016;127:2375\u201390. https:\/\/doi.org\/10.1182\/blood-2016-01-643569.","journal-title":"Blood"},{"key":"3792_CR9","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1182\/blood-2014-11-610436","volume":"125","author":"J Reichel","year":"2015","unstructured":"Reichel J, Chadburn A, Rubinstein PG, Giulino-Roth L, Tam W, Liu Y, et al. Flow sorting and exome sequencing reveal the oncogenome of primary hodgkin and Reed-Sternberg cells. Blood. 2015;125:1061\u201372. https:\/\/doi.org\/10.1182\/blood-2014-11-610436.","journal-title":"Blood"},{"key":"3792_CR10","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1182\/blood-2017-11-814913","volume":"131","author":"E Tiacci","year":"2018","unstructured":"Tiacci E, Ladewig E, Schiavoni G, Penson A, Fortini E, Pettirossi V, et al. Pervasive mutations of JAK-STAT pathway genes in classical hodgkin lymphoma. Blood. 2018;131:2454\u201365. https:\/\/doi.org\/10.1182\/blood-2017-11-814913.","journal-title":"Blood"},{"key":"3792_CR11","doi-asserted-by":"publisher","first-page":"4065","DOI":"10.1182\/bloodadvances.2019001012","volume":"3","author":"K Wienand","year":"2019","unstructured":"Wienand K, Chapuy B, Stewart C, Dunford AJ, Wu D, Kim J, et al. Genomic analyses of flow-sorted hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion. Blood Adv. 2019;3:4065\u201380. https:\/\/doi.org\/10.1182\/bloodadvances.2019001012.","journal-title":"Blood Adv"},{"key":"3792_CR12","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S1470-2045(20)30601-X","volume":"22","author":"P Borchmann","year":"2021","unstructured":"Borchmann P, Pl\u00fctschow A, Kobe C, Greil R, Meissner J, Topp MS, et al. PET-guided omission of radiotherapy in early-stage unfavourable hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22:223\u201334. https:\/\/doi.org\/10.1016\/S1470-2045(20)30601-X.","journal-title":"Lancet Oncol"},{"key":"3792_CR13","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1200\/JCO.19.00964","volume":"37","author":"M Fuchs","year":"2019","unstructured":"Fuchs M, Goergen H, Kobe C, Kuhnert G, Lohri A, Greil R, et al. Positron emission Tomography\u2013Guided treatment in Early-Stage favorable hodgkin lymphoma: final results of the International, randomized phase III HD16 trial by the German hodgkin study group. J Clin Oncol. 2019;37:2835\u201345. https:\/\/doi.org\/10.1200\/JCO.19.00964.","journal-title":"J Clin Oncol"},{"key":"3792_CR14","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1056\/NEJMra1003733","volume":"363","author":"JO Armitage","year":"2010","unstructured":"Armitage JO. Early-Stage hodgkin\u2019s lymphoma. N Engl J Med. 2010;363:653\u201362. https:\/\/doi.org\/10.1056\/NEJMra1003733.","journal-title":"N Engl J Med"},{"key":"3792_CR15","unstructured":"Borchmann S, Lymphovista. HL\u2014a validated assay for genotyping and MRD assessment in hodgkin lymphoma. ASH; 2024."},{"key":"3792_CR16","doi-asserted-by":"crossref","unstructured":"Boegeholz J. Ultrasensitive Circulating tumor DNA MRD status predicts treatment failure & complements PET\/CT throughout treatment for early and advanced stage classic Hodgkin Lymphoma, ASH; 2024.","DOI":"10.1182\/blood-2024-201877"},{"key":"3792_CR17","unstructured":"The Origin and Mechanism of Circulating DNA - STROUN \u2013\u20092000 - Annals of the New York Academy of Sciences. - Wiley Online Library n.d. https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/abs\/10.1111\/j.1749-6632.2000.tb06608.x?sid=nlm&#x0025;3Apubmed. Accessed 17 Sep 2023."},{"key":"3792_CR18","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/s41586-023-06903-x","volume":"625","author":"SK Alig","year":"2024","unstructured":"Alig SK, Esfahani MS, Garofalo A, Li MY, Rossi C, Flerlage T, et al. Distinct hodgkin lymphoma subtypes defined by noninvasive genomic profiling. Nature. 2024;625:778\u201387. https:\/\/doi.org\/10.1038\/s41586-023-06903-x.","journal-title":"Nature"},{"key":"3792_CR19","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1182\/blood-2017-11-812073","volume":"131","author":"V Spina","year":"2018","unstructured":"Spina V, Bruscaggin A, Cuccaro A, Martini M, Di Trani M, Forestieri G, et al. Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical hodgkin lymphoma. Blood. 2018;131:2413\u201325. https:\/\/doi.org\/10.1182\/blood-2017-11-812073.","journal-title":"Blood"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03792-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-03792-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03792-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T09:39:32Z","timestamp":1763545172000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-03792-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3792"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-03792-6","relation":{},"ISSN":["2730-6011"],"issn-type":[{"type":"electronic","value":"2730-6011"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"assertion":[{"value":"27 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article has been updated to amend the missing funding acknowledgement.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2054"}}